Patents by Inventor Eric A. Ariazi

Eric A. Ariazi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of using estrogen-related receptor alpha (ERR?) status to determine prognosis, treatment strategy and predisposition to breast cancer, and method of using ERR? as a therapeutic target for the treatment of breast cancer
    Patent number: 7541141
    Abstract: The present invention provides that ERR? is a breast cancer biomarker of clinical course and treatment sensitivity and, itself, a target for breast cancer treatment. A high ERR? level in breast cancer indicates poor prognosis. Analyzing ERR? expression level along with the status of ER? and ErbB2 can help breast cancer patients make treatment choices. Furthermore, breast cancer can be treated by modulating ERR? activity.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: June 2, 2009
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Janet E. Mertz, Stephen D. Johnston, Richard J. Kraus, Eric A. Ariazi
  • Cellular Arrays
    Publication number: 20080108513
    Abstract: The present invention relates to characterizing transcription within cells. In particular, the present invention provides transfected cell arrays (e.g., two-dimensional and/or three-dimensional arrays) and systems, kits and methods utilizing the same (e.g., for transcriptional activity characterization). Compositions and methods of the present invention find use in, among other things, research, drug discovery and clinical (e.g., diagnostic, preventative and therapeutic) applications.
    Type: Application
    Filed: June 1, 2007
    Publication date: May 8, 2008
    Applicant: Northwestern University
    Inventors: Angela K. Pannier, Eric A. Ariazi, V. Craig Jordan, Lonnie D. Shea
  • Method of using estrogen-related receptor alpha (ERRalpha) status to determine prognosis, treatment strategy and predisposition to breast cancer, and method of using ERRalpha as a therapeutic target for the treatment of breast cancer
    Publication number: 20030152959
    Abstract: The present invention provides that ERR&agr; is a breast cancer biomarker of clinical course and treatment sensitivity and, itself, a target for breast cancer treatment. A high ERR&agr; level in breast cancer indicates poor prognosis. Analyzing ERR&agr; expression level along with the status of ER&agr; and ErbB2 can help breast cancer patients make treatment choices. Furthermore, breast cancer can be treated by modulating ERR&agr; activity.
    Type: Application
    Filed: September 5, 2002
    Publication date: August 14, 2003
    Inventors: Janet E. Mertz, Stephen D. Johnston, Richard J. Kraus, Eric A. Ariazi
  • Identification of differentially expressed genes
    Patent number: 5700644
    Abstract: Methods are disclosed to identify differentially expressed genes. In one aspect, one uses subtractive hybridization to enrich for candidate genes, followed by a PCR amplified radiolabeled display of cDNA products of the hybridization. Specially modified primer binding regions are used that can be achieved either through use of trimming plasmids or non-symmetric display plasmids.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 23, 1997
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Michael N. Gould, Eric A. Ariazi